CellFX Treat & Resect BCC Feasibility Study

  • days left to enroll
  • participants needed
  • sponsor
    Pulse Biosciences, Inc.
Updated on 17 June 2021
William A. Knape
Primary Contact
Palm Harbor Dermatology (5.7 mi away) Contact
+5 other location


This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.


The study will enroll healthy adult subjects with confirmed low-risk BCC lesion(s) by biopsy, excluding BCCs located on the face, neck, scalp, axilla, hands, feet, and genitals not exceeding 1.5 cm. Macrophotography of all study BCCs will be captured and clinically assessed by the site investigator for characterization of healing and scar appearance prior to and post-surgical excision. All subjects will be followed at 3, 7, 14, 30 and 60-days post-CellFX procedure and at 14, 30 and 60-days post-excision. Adverse events will be documented.

Condition Basal cell carcinoma, Excision Margin, basal cell carcinomas, basal cell carcinoma of skin
Treatment CellFX System
Clinical Study IdentifierNCT04918381
SponsorPulse Biosciences, Inc.
Last Modified on17 June 2021


Yes No Not Sure

Inclusion Criteria

Subject is at least 22 and no older than 85 years of age
Subject has 1-2 primary, non-recurrent, superficial, or nodular visible basal cell carcinoma lesion up to 1.5 cm in size with well-defined borders that has been verified by biopsy
Lesion(s) is appropriate for full linear excision with 5 mm margins
Subject is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
Subject gives voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained
Subject is willing to have BCC lesion(s) treated in a single treatment session and must comply with all study procedures including follow-up visits
Subject consents to have photographs taken of the BCC lesion(s)
Subject agrees to refrain from using all other lesion removal products or treatments (topical medication including over-the-counter medications or treatments from PI or another physician) during the study period
Subject agrees to refrain from prolonged sun exposure of the treatment area during the study period

Exclusion Criteria

Subject has an implantable electronic medical device (i.e., pacemaker, implantable cardioverter defibrillator)
Subject has an active infection or history of infection in designated test area within four weeks prior to treatment
Subject is not willing or able to sign the Informed Consent
Subject is known to be immune compromised/has a history of immunosuppression (e.g., organ transplant, long-term use of psoralen) or genetic disease (e.g., nevoid basal cell carcinoma syndrome [Gorlin syndrome], xeroderma pigmentosum)
The basal cell carcinoma lesion intended for treatment with the CellFX System is on the face, neck, scalp, axilla, hands, feet, or genitals
The basal cell carcinoma intended for treatment with the CellFX System is a high-risk BCC subtype including perineurial, infiltrative, sclerosing, morpheaform, desmoplastic, micronodular, basosquamous or exhibiting aggressive growth patterns
Subject is known to be a keloid producer
Subject has allergies to Lidocaine or Lidocaine-like products
Subject has a history of radiation to the area intended for treatment
Subject has current or prior metastatic BCC
Subject is currently being treated or has been previously treated with Sonidegib or Vismodegib
Subject has recurrent BCC lesions
Subject has a systemic infection
Subject has a history of epilepsy
Subject has a history of cardiac arrhythmia, myocardial infarction or structural heart disease
Subject is employed by the sponsor, clinic site, or entity associated with the conduct of the study
Subject has any condition or situation which, in the Investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study
Subject has a history of use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study, with the exception of participation in a COVID vaccination related clinical trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note